作者
Stein Bergan, Mercè Brunet, Dennis A Hesselink, Kamisha L Johnson-Davis, Pawel K Kunicki, Florian Lemaitre, Pierre Marquet, Mariadelfina Molinaro, Ofelia Noceti, Smita Pattanaik, Tomasz Pawinski, Christoph Seger, Maria Shipkova, Jesse J Swen, Teun van Gelder, Raman Venkataramanan, Eberhard Wieland, Jean-Baptiste Woillard, Tom C Zwart, Markus J Barten, Klemens Budde, Maja-Theresa Dieterlen, Laure Elens, Vincent Haufroid, Satohiro Masuda, Olga Millan, Tomoyuki Mizuno, Dirk JAR Moes, Michael Oellerich, Nicolas Picard, Linda Salzmann, Burkhard Tönshoff, Ron HN van Schaik, Nils Tore Vethe, Alexander A Vinks, Pierre Wallemacq, Anders Åsberg, Loralie J Langman
发表日期
2021/4/1
来源
Therapeutic drug monitoring
卷号
43
期号
2
页码范围
150-200
出版商
LWW
简介
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized dosing has led to development of methods to estimate MPA area under the curve based on the measurement of drug concentrations in only a few samples. This approach is feasible in the clinical routine and has proven successful in terms of correlation with outcome. However, the search for superior correlates has continued, and numerous studies in search of biomarkers that could better predict the perfect dosage for the individual patient have been published. As it was considered timely for an updated and comprehensive presentation of consensus on the status for personalized treatment with MPA, this report was prepared following an initiative from members of the International Association of Therapeutic Drug …
学术搜索中的文章
S Bergan, M Brunet, DA Hesselink, KL Johnson-Davis… - Therapeutic drug monitoring, 2021